Mary O'Connell
Friday, January 2, 2026
When healthcare M&A hits the cold chain
The $4.8 billion acquisition of Amicus Therapeutics by BioMarin is, on its surface, a familiar healthcare story: portfolio expansion, accelerated revenue growth, and a stronger foothold in the rare disease market. But beneath the financial headlines sits a less visible and increasingly critical reality. For supply chain and cold chain professionals, deals like this are […]
